טוען...
Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial
OBJECTIVE: This study evaluated the safety and preliminary efficacy of vorolanib, a novel tyrosine kinase inhibitor, for treatment of patients with advanced solid tumors. METHODS: During dose escalation, patients received increasing doses of oral vorolanib (50−250 mg once daily) in cycles of four we...
שמור ב:
| הוצא לאור ב: | Chin J Cancer Res |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AME Publishing Company
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7941683/ https://ncbi.nlm.nih.gov/pubmed/33707933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21147/j.issn.1000-9604.2021.01.11 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|